Search
Lemuteporfin
go.drugbank.com/drugs/DB04980InvestigationalLemuteporfin, under development by QLT Incorporated, is a benzoporphyrin-derived chlorin-like photosensitizer. It is intended for the treatment of beign prostatic hyperplasia.
Irofulven
go.drugbank.com/drugs/DB05786InvestigationalA novel anti-cancer compound synthesized by scientists at the University of California, San Diego more than a decade ago from toxins of the poisonous jack-o-lantern mushroom, has been granted “fast track” status by the U.S. Food and Drug...
Oleoyl-estrone
go.drugbank.com/drugs/DB04870InvestigationalOleoyl-estrone (OE) is a fatty acid ester of estrone. This hormone occurs naturally and is found circulating in various animal species and humans. It has been shown in animal studies to promote the loss of body fat while maintaining body...
Nangibotide
go.drugbank.com/drugs/DB16247InvestigationalNangibotide is under investigation in clinical trial NCT04055909 (Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock).
Pomaglumetad methionil
go.drugbank.com/drugs/DB05096InvestigationalLY2140023 is an investigational drug from Lilly, which is being developed as a new treatment option for schizophrenia.
Resveratrol
go.drugbank.com/drugs/DB02709InvestigationalIt exists as cis-(Z) and trans-(E) isomers. The trans- form can undergo isomerisation to the cis- form when heated or exposed to ultraviolet irradiation. In a 2004 issue of Science, Dr. … Sinclair of Harvard University said resveratrol is not an easy molecule to protect from oxidation. It has been claimed that it is readily degraded by exposure to light, heat, and oxygen.
Etesevimab
go.drugbank.com/drugs/DB15897InvestigationalEtesevimab (LY-CoV016, also known as JS016) is a fully human and recombinant monoclonal antibody that targets the SARS-CoV-2 surface spike protein receptor binding domain.
Ifenprodil
go.drugbank.com/drugs/DB08954ApprovedInvestigationalWithdrawn[A220133] Further studies elucidated that ifenprodil binds strongly at the inter-subunit interface of adjacent GluN1 and GluN2B NTDs, where it acts as a non-competitive antagonist.
Human cord blood hematopoietic progenitor cell
go.drugbank.com/drugs/DB11054ApprovedHemacord is marketed in the U.S. as an allogeneic cord blood hematopoietic progenitor cell therapy for intravenous use.